Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDPHL01 in Female Subjects With Androgenetic Alopecia
NCT07146022Phase 3Active, not recruiting
- Sponsor
- Veradermics
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VDPHL01 in androgenetic alopecia (AGA) (4 arms), sponsored by Veradermics. Primary endpoints: Target Area Hair Counts at 6 months and Subjects Evaluation of Treatment Benefit at 6 months. Started Jul 2025; status: active, not recruiting.
02
Drugs
VDPHL01
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07146022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146022.